Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Identifying potential germline variants from sequencing hematopoietic malignancies

Ira L. Kraft, Lucy A. Godley

Blood (2020) 136 (22): 2498–2506.

https://doi.org/10.1182/blood.2020006910

Published: 2020

Journal Articles

New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies

Amy M Trottier, MDBSc,MSc, Ira L Kraft, MD, Lawrence J Druhan, PhD, Amanda Lance, MS, Belinda R Avalos, MD, Lucy A Godley, MD PhD

Blood (2019) 134 (Supplement_1): 2543.

https://doi.org/10.1182/blood-2019-129492

Published: 2019

Journal Articles

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance

Blood (2015) 125 (11): 1772–1781.

https://doi.org/10.1182/blood-2014-08-588855

Published: 2015

Includes: Supplemental data

Journal Articles

Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders

William L. Heaton, M.S., Anna M. Eiring, PhD, Nadeem A. Vellore, PhD, Diana Resetca, B.S., Sina Haftchenary, PhD, David Rosa, PhD, Ahmed M. Ali, Anna V. Senina, M.S., Anthony D. Pomicter, M.S., Brent D.G. Page, PhD, Ira L. Kraft, B.S., Kimberly R. Reynolds, M.S., Derek J. Wilson, PhD, Riccardo Baron, PhD, Thomas O'Hare, PhD, Patrick T. Gunning, PhD, Michael W. Deininger

Blood (2014) 124 (21): 4816.

https://doi.org/10.1182/blood.V124.21.4816.4816

Published: 2014

Journal Articles

Direct Contact With Bone Marrow Stromal Cells Protects CML Progenitors From Imatinib Through Cytoplasmic Stabilization Of β-Catenin

Anna M. Eiring, PhD, David J. Anderson, MBA, Tian Y. Zhang, MD, PhD, Ira L. Kraft, BS, Kimberly R. Reynolds, MS, Anthony D. Pomicter, MS, Clinton C. Mason, PhD, Thomas O'Hare, Michael W. Deininger, MD, PhD

Blood (2013) 122 (21): 3982.

https://doi.org/10.1182/blood.V122.21.3982.3982

Published: 2013

Journal Articles

An Unbiased shRNA Library Screen Identifies Nucleocytoplasmic Transport As a Potential Target For Treatment Of Chronic Myeloid Leukemia

Jamshid Sorouri Khorashad, MD, PhD, FRCPath, Clinton C. Mason, PhD, Ira L. Kraft, BS, Kimberly R. Reynolds, MS, Anthony D. Pomicter, MS, Anna M. Eiring, PhD, Matthew S. Zabriskie, Anthony J Iovino, William Heaton, Srinivas K. Tantravahi, MBBS, MRCP, Michael Kauffman, MD, PhD, Sharon Schacham, PhD, MBA, Alex Chenchik, PhD, Kyle Bonneau, PhD, Thomas O'Hare, Michael W. Deininger, MD, PhD

Blood (2013) 122 (21): 2707.

https://doi.org/10.1182/blood.V122.21.2707.2707

Published: 2013

Journal Articles

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Ira L. Kraft, BS, Brent D.G. Page, PhD, Tian Y. Zhang, MD, PhD, Jamshid S. Khorashad, MD, PhD, FRCPath, Nadeem A. Vellore, PhD, Kimberly R. Reynolds, MS, Anthony D. Pomicter, MS, Anna V. Senina, MS, Matthew S. Zabriskie, BS, Shazia Ahmad, Clinton C. Mason, PhD, Richard Moriggl, PhD, Riccardo Baron, PhD, Thomas O'Hare, Patrick T. Gunning, PhD, Michael W. Deininger

Blood (2013) 122 (21): 854.

https://doi.org/10.1182/blood.V122.21.854.854

Published: 2013

Journal Articles

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Blood (2013) 121 (3): 489–498.

https://doi.org/10.1182/blood-2012-05-431379

Published: 2013

Includes: Supplemental data

Journal Articles

STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)

Anna M. Eiring, PhD, Ira L Kraft, BS, Brent DG Page, BS, David J Anderson, BA, Zhimin Gu, PhD, Jamshid S Khorashad, MD, PhD, Anthony D Pomicter, MS, Kimberly R Reynolds, MS, Matthew S Zabriskie, BS, Richard Moriggl, PhD, Patrick T Gunning, PhD, Thomas O'Hare, PhD, Michael W Deininger, MD, PhD

Blood (2012) 120 (21): 31.

https://doi.org/10.1182/blood.V120.21.31.31

Published: 2012

Journal Articles

Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.

Ira L Kraft, BS, Anna M. Eiring, PhD, Brent DG Page, BS, Clinton C Mason, PhD, Zhimin Gu, PhD, Jamshid S Khorashad, MD, PhD, David J Anderson, BA, Anthony D Pomicter, MS, Kimberly R Reynolds, MS, Johanna Estrada, Matthew S Zabriskie, BS, Patrick T Gunning, PhD, Thomas O'Hare, PhD, Michael W Deininger, MD, PhD

Blood (2012) 120 (21): 2445.

https://doi.org/10.1182/blood.V120.21.2445.2445

Published: 2012

Journal Articles

Intrinsic and Extrinsic Survival Signals Converge on STAT3 As a Critical Mediator of BCR-ABL-Independent Tyrosine Kinase Inhibitor Resistance,

Anna M Eiring, PhD, Ira L Kraft, BS, David J Anderson, BS, Elie Traer, MD, PhD, Qian Yu, BS, Jamshid Khorashad, MD, PhD, Thomas O'Hare, Michael W. Deininger

Blood (2011) 118 (21): 3742.

https://doi.org/10.1182/blood.V118.21.3742.3742

Published: 2011

Journal Articles

Frequency and Clonality of BCR-ABL Compound Mutations in Chronic Myeloid Leukemia,

Jamshid Khorashad, MD, PhD, Todd W. Kelley, MD, Philippe Szankasi, PhD, Lauren T. Adrian, Christopher A. Eide, Matthew S. Zabriskie, Thoralf Lange, MD, Ira L Kraft, BS, Anna M Eiring, PhD, Thomas O'Hare, Michael W. Deininger

Blood (2011) 118 (21): 3744.

https://doi.org/10.1182/blood.V118.21.3744.3744

Published: 2011

NARROW

Identifying potential germline variants from sequencing hematopoietic malignancies

New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance

Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders

Direct Contact With Bone Marrow Stromal Cells Protects CML Progenitors From Imatinib Through Cytoplasmic Stabilization Of β-Catenin

An Unbiased shRNA Library Screen Identifies Nucleocytoplasmic Transport As a Potential Target For Treatment Of Chronic Myeloid Leukemia

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)

Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.

Intrinsic and Extrinsic Survival Signals Converge on STAT3 As a Critical Mediator of BCR-ABL-Independent Tyrosine Kinase Inhibitor Resistance,

Frequency and Clonality of BCR-ABL Compound Mutations in Chronic Myeloid Leukemia,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only